Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Activating somatic mutations in the epidermal growth factor receptor (EGFR) are key drivers in non-small cell lung cancer (NSCLC).
• While EGFR L858R and exon 19 deletions are common, exon 20 insertions represent a distinct mutation class in NSCLC.
• These exon 20 insertion mutations are associated with intrinsic resistance to standard EGFR tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To investigate the structural and dynamic consequences of common EGFR exon 20 insertions (V769insASV and D770insNPG) within the EGFR kinase domain.
• To elucidate the molecular mechanisms underlying the increased enzymatic activity and TKI insensitivity of these EGFR mutants.

Main Methods:

• Utilized molecular dynamics (MD) simulations to model wild-type EGFR and EGFR variants with exon 20 insertions (V769insASV, D770insNPG).
• Analyzed both active and inactive conformations to assess local and global structural alterations.
• Focused on key structural elements including the αC helix, Lys745-Glu762 salt bridge, DFG-motif, R-spine, and P-loop.

Main Results:

• EGFR exon 20 insertions stabilize the active conformation by enhancing interactions that stabilize the αC helix.
• The mutations preserve the Lys745-Glu762 salt bridge and the DFG-motif/R-spine in a conformation conducive to activity.
• Insertions alter the P-loop structure near the ATP-binding pocket and disrupt the Ala767-Arg776 interaction crucial for the inactive state, promoting transition to the active state.

Conclusions:

• EGFR exon 20 insertions confer distinct structural and dynamic properties compared to wild-type EGFR.
• These alterations promote a more stable active conformation and hinder the formation of the inactive state, contributing to oncogenesis.
• The structural changes, particularly near the ATP-binding site, provide a mechanistic basis for the observed clinical resistance to TKIs in NSCLC patients with EGFR exon 20 insertions.